AZN logo

AZNAstraZeneca PLC

$182.28
$3.32
(1.85%)
Today
Closed $182.28
$1.11
(0.61%)
After Hours
Updated: 07:57 PM EDT
Reported EarningsApr 29
Mkt Cap$282.69B
Vol1.75M
64

Bullish Sentiment

How do you feel about AZN?

News
all
press releases
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
In the most recent trading session, Astrazeneca (AZN) closed at $182.28, indicating a +1.86% shift from the previous trading day.
Zacks
News Placeholder
More News
News Placeholder
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Zacks
News Placeholder
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Zacks
News Placeholder
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...
Benzinga
News Placeholder
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...
Benzinga
News Placeholder
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
Zacks
News Placeholder
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.
Stocktwits
News Placeholder
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...
Benzinga
News Placeholder
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...
Benzinga
News Placeholder
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Zacks
<
1
2
...
>

Advertisement|Remove ads.